GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options
GHAPPcast22 Loka 2025

GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options

Thank you to Ardelyx for your support on this podcast episode.

In this podcast, Gabriella McCarty, NP, and Kimberly Orleck, PA-C, dive into the complexities of irritable bowel syndrome with constipation (IBS-C) and the wide range of therapies available to help patients. They discuss the importance of taking a thorough patient history to understand whether the primary symptom is constipation, bloating, abdominal pain, or overflow diarrhea—emphasizing that IBS-C treatment is not one-size-fits-all. Gabriella and Kim break down the differences between over-the-counter therapies like fiber and osmotic laxatives, which often help with bowel movements but do little for abdominal pain, and FDA-approved prescription options that also address visceral hypersensitivity, bloating, and global IBS symptoms. They explain how secretagogues and retenagogues work, set realistic expectations around therapy timelines, and highlight the importance of preparing patients for possible side effects such as diarrhea or nausea. By focusing on patient education, shared decision-making, and scheduled follow-up visits, they empower patients to better understand their condition and stay engaged in their care. This conversation provides practical guidance for both GI providers and patients navigating IBS-C management. For more educational resources, visit GHAPP.org and download the GHAPP ACE App.

#IBSC #IrritableBowelSyndrome #Gastroenterology #DigestiveHealth #GutHealth #GIHealth #IBSManagement #IBSConstipation #PatientEducation #GHAPPcast

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(154)

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Touko 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Touko 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Touko 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Touko 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Huhti 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Huhti 23min

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...

14 Huhti 18min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
rss-pitaisko-erota
tiedenaiset-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
voi-hyvin-meditaatiot-2
rss-narsisti
rss-kuumilla-aalloilla
puhu-muru
rss-uplevel-by-sonja-hannus
katilon-kahvitunti
meditaatiot-suomeksi
terapiassa
rss-nautinto
traumapodi
rss-terapiaklubi
monisuhteellista
fitnessvastaanotto
rss-palaudu-synnytyksesta-podcast
rss-hereilla